Search

Your search keyword '"Munshi, Nikhil C"' showing total 16 results
Start Over Author "Munshi, Nikhil C" Journal leukemia
16 results on '"Munshi, Nikhil C"'

2. Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma

Author

Waldschmidt, Johannes M., Yee, Andrew J., Vijaykumar, Tushara, Pinto, Ricardo A., Frede, Julia, Anand, Praveen, Bianchi, Giada, Guo, Guangwu, Potdar, Sayalee, Seifer, Charles, Nair, Monica S., Kokkalis, Antonis, Kloeber, Jake A., Shapiro, Samantha, Budano, Lillian, Mann, Mason, Friedman, Robb, Lipe, Brea, Campagnaro, Erica, O’Donnell, Elizabeth K., Zhang, Cheng-Zhong, Laubach, Jacob P., Munshi, Nikhil C., Richardson, Paul G., Anderson, Kenneth C., Raje, Noopur S., Knoechel, Birgit, and Lohr, Jens G.

Published
2022
Full Text
View/download PDF

4. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma

Author

An, Gang, Yan, Yuting, Xu, Yan, Mao, Xuehan, Liu, Jiahui, Fan, Huishou, Wang, Qi, Du, Chenxing, Li, Zengjun, Yi, Shuhua, Lv, Rui, Deng, Shuhui, Sui, Weiwei, Fu, Mingwei, Hao, Mu, Huang, Wenyang, Zou, Dehui, Zhao, Yaozhong, Yuan, Chenglu, Du, Xin, Wang, Jianxiang, Cheng, Tao, Tai, Yu-Tzu, Munshi, Nikhil C., and Qiu, Lugui

Published
2020
Full Text
View/download PDF

7. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups

Author

Bolli, Niccolo, Biancon, Giulia, Moarii, Matahi, Gimondi, Silvia, Li, Yilong, de Philippis, Chiara, Maura, Francesco, Sathiaseelan, Vijitha, Tai, Yu-Tzu, Mudie, Laura, O’Meara, Sarah, Raine, Keiran, Teague, Jon W., Butler, Adam P., Carniti, Cristiana, Gerstung, Moritz, Bagratuni, Tina, Kastritis, Efstathios, Dimopoulos, Meletios, Corradini, Paolo, Anderson, Kenneth C., Moreau, Philippe, Minvielle, Stephane, Campbell, Peter J., Papaemmanuil, Elli, Avet-Loiseau, Herve, and Munshi, Nikhil C.

Published
2018
Full Text
View/download PDF

8. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

Author

Samur, Mehmet Kemal, Minvielle, Stephane, Gulla, Annamaria, Fulciniti, Mariateresa, Cleynen, Alice, Aktas Samur, Anil, Szalat, Raphael, Shammas, Masood, Magrangeas, Florence, Tai, Yu-Tzu, Auclair, Daniel, Keats, Jonathan, Richardson, Paul, Attal, Michel, Moreau, Philippe, Anderson, Kenneth C., Parmigiani, Giovanni, Avet-Loiseau, Hervé, and Munshi, Nikhil C.

Published
2018
Full Text
View/download PDF

9. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity

Author

Amodio, Nicola, Stamato, Maria Angelica, Juli, Giada, Morelli, Eugenio, Fulciniti, Mariateresa, Manzoni, Martina, Taiana, Elisa, Agnelli, Luca, Cantafio, Maria Eugenia Gallo, Romeo, Enrica, Raimondi, Lavinia, Caracciolo, Daniele, Zuccalà, Valeria, Rossi, Marco, Neri, Antonino, Munshi, Nikhil C., Tagliaferri, Pierosandro, and Tassone, Pierfrancesco

Published
2018
Full Text
View/download PDF

11. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing

Author

Guo, Guangwu, Raje, Noopur S., Seifer, Charles, Kloeber, Jake, Isenhart, Randi, Ha, Gavin, Yee, Andrew J., O’Donnell, Elizabeth K., Tai, Yu-Tzu, Richardson, Paul G., Bianchi, Giada, Laubach, Jacob P., Warren, Diane, Gemme, Erica, Voisine, Jordan, Frede, Julia, Kokkalis, Antonis, Yun, Huiyoung, Dimitrova, Valeriya, Vijaykumar, Tushara, Meyerson, Matthew, Munshi, Nikhil C., Anderson, Kenneth C., Knoechel, Birgit, and Lohr, Jens G.

Published
2018
Full Text
View/download PDF

13. Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma

Author

Gullà, Annamaria, Hideshima, Teru, Bianchi, Giada, Fulciniti, Mariateresa, Samur, Mehmet Kemal, Qi, Jun, Tai, Yu-Tzu, Harada, Takeshi, Morelli, Eugenio, Amodio, Nicola, Carrasco, Ruben, Tagliaferri, Pierosandro, Munshi, Nikhil C., Tassone, Pierfrancesco, and Anderson, Kenneth C.

Subjects
Protein-Arginine N-Methyltransferases, Pyrimidines, Ribonucleoproteins, Cell Line, Tumor, NF-kappa B, Animals, Humans, Isoquinolines, Multiple Myeloma, Prognosis, Article, Cell Proliferation, Signal Transduction
Abstract

Arginine methyltransferases critically regulate cellular homeostasis by modulating the functional outcome of their substrates. The protein arginine methyltransferase 5 (PRMT5) is an enzyme involved in growth and survival pathways promoting tumorigenesis. However, little is known about the biologic function of PRMT5 and its therapeutic potential in multiple myeloma (MM). In the present study, we identified and validated PRMT5 as a new therapeutic target in MM. PRMT5 is overexpressed in patient MM cells and associated with decreased progression-free survival and overall survival. Either genetic knockdown or pharmacological inhibition of PRMT5 with the inhibitor EPZ015666 significantly inhibited growth of both cell lines and patient MM cells. Furthermore, PRMT5 inhibition abrogated NF-κB signaling. Interestingly, mass spectrometry identified a tripartite motif-containing protein 21 TRIM21 as a new PRMT5-partner, and we delineated a TRIM21-dependent mechanism of NF-κB inhibition. Importantly, oral administration of EPZ015666 significantly decreased MM growth in a humanized murine model of MM. These data both demonstrate the oncogenic role and prognostic relevance of PRMT5 in MM pathogenesis, and provide the rationale for novel therapies targeting PRMT5 to improve patient outcome.

Published
2017

14. Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma

Author

An, Gang, primary, Yan, Yuting, additional, Xu, Yan, additional, Mao, Xuehan, additional, Liu, Jiahui, additional, Fan, Huishou, additional, Wang, Qi, additional, Du, Chenxing, additional, Li, Zengjun, additional, Yi, Shuhua, additional, Lv, Rui, additional, Deng, Shuhui, additional, Sui, Weiwei, additional, Fu, Mingwei, additional, Hao, Mu, additional, Huang, Wenyang, additional, Zou, Dehui, additional, Zhao, Yaozhong, additional, Yuan, Chenglu, additional, Du, Xin, additional, Wang, Jianxiang, additional, Cheng, Tao, additional, Tai, Yu-Tzu, additional, Munshi, Nikhil C., additional, and Qiu, Lugui, additional

Published
2019
Full Text
View/download PDF

16. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

Author

Bae, Jooeun, Samur, Mehmet, Richardson, Paul, Munshi, Nikhil C., and Anderson, Kenneth C.

Abstract

To expand the breadth and extent of current multiple myeloma (MM)-specific immunotherapy, we have identified various antigens on CD138+tumor cells from newly diagnosed MM patients (n= 616) and confirmed B-cell maturation antigen (BCMA) as a key myeloma-associated antigen. The aim of this study is to target the BCMA, which promotes MM cell growth and survival, by generating BCMA-specific memory CD8+CTL that mediate effective and long-lasting immunity against MM. Here we report the identification of novel engineered peptides specific to BCMA, BCMA72-80(YLMFLLRKI), and BCMA54-62(YILWTCLGL), which display improved affinity/stability to HLA-A2 compared to their native peptides and induce highly functional BCMA-specific CTL with increased activation (CD38, CD69) and co-stimulatory (CD40L, OX40, GITR) molecule expression. Importantly, the heteroclitic BCMA72-80specific CTL demonstrated poly-functional Th1-specific immune activities [IFN-γ/IL-2/TNF-α production, proliferation, cytotoxicity] against MM, which were correlated with expansion of Tetramer+and memory CD8+CTL. Additionally, heteroclitic BCMA72-80specific CTL treated with anti-OX40 (immune agonist) or anti-LAG-3 (checkpoint inhibitor) display increased immune function, mainly by central memory CTL. These results provide the framework for clinical application of heteroclitic BCMA72-80peptide, alone and in combination with anti-LAG3 and/or anti-OX40 therapy, in vaccination and/or adoptive immunotherapeutic strategies to generate long-lasting anti-tumor immunity in patients with MM or other BCMA expressing tumors.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results